Ligand Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Ligand Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Ligand Pharmaceuticals Inc Strategy Report
- Understand Ligand Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help biopharmaceutical companies in the discovery and development of medicines. Its major research technologies include formulation science, structure-based drug design, antibody discovery technologies and liver targeted pro-drug technologies, which assist pharmaceutical companies in securing approval for prescription drugs. Its technologies and research capabilities contributed to the development of a diversified portfolio of biotechnology and pharmaceutical products for the inflammatory, respiratory central nervous system, oncology, ophthalmology, hematology, musculoskeletal disorder, and osteoporosis, among others. Ligand also offers late-stage development, regulatory management, and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.
Ligand Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Technologies: | - |
Captisol (Uniquely Modified Cyclodextrin) | OmniRat |
OmniAb (Therapeutic Antibody Platform) | OmniAb |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In January, the company's Zelsuvmi (berdazimer topical gel, 10.3%) received approval from the US Food and Drug Administration for molluscum contagiosum. |
2023 | Contracts/Agreements | In December, the company expanded its partnership with Palvella Therapeutics to accelerate Phase 3 development of QTORIN rapamycin for the treatment of Microcystic Lymphatic Malformations. |
2023 | Acquisitions/Mergers/Takeovers | In November, the company acquired Tolerance Therapeutics, Inc. |
Competitor Comparison
Key Parameters | Ligand Pharmaceuticals Inc | Gilead Sciences Inc | Regeneron Pharmaceuticals Inc | TransGenic Inc | Atara Biotherapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | Japan | United States of America |
City | San Diego | Foster City | Tarrytown | Fukuoka-Shi | Thousand Oaks |
State/Province | California | California | New York | Fukuoka | California |
No. of Employees | 58 | 18,000 | 13,450 | 236 | 308 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
John W. Kozarich, Ph.D. | Chairman | Executive Board | 2007 | 73 |
Todd C. Davis | Chief Executive Officer | Executive Board | 2022 | 62 |
Tavo Espinoza | Chief Financial Officer | Senior Management | 2022 | - |
Matthew Korenberg | President; Chief Operating Officer | Senior Management | 2022 | - |
Andrew Reardon | Chief Legal Officer | Senior Management | 2022 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward